An open-label, randomised, parallel-group comparison to investigate the efficacy of Yasmin (30 microg ethinylestradiol, 3mg drospirenone) and Marvelon (30 microg ethinylestradiol, 150 microg desogestrel) on cycle control in healthy Chinese women over 13 cycles

Trial Profile

An open-label, randomised, parallel-group comparison to investigate the efficacy of Yasmin (30 microg ethinylestradiol, 3mg drospirenone) and Marvelon (30 microg ethinylestradiol, 150 microg desogestrel) on cycle control in healthy Chinese women over 13 cycles

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Drospirenone/ethinylestradiol (Primary) ; Ethinylestradiol/desogestrel
  • Indications Pregnancy
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 13 Jan 2009 Additional trial identifier 91330 reported by ClinicalTrials.gov.
    • 13 Jan 2009 Planned patient number added (842) as reported by ClinicalTrials.gov.
    • 13 Jan 2009 Actual end date (Mar 2006) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top